“Safety of Empagliflozin As Add-on Therapy in Patients With Uncontrolled Type 2 Diabetes Mellitus”. 2026. KYAMC Journal 16 (3): 119-22. https://doi.org/10.3329/kyamcj.v16i3.88022.